Wealth Enhancement Advisory Services LLC Buys 8,975 Shares of Exelixis, Inc. $EXEL

Wealth Enhancement Advisory Services LLC increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 8.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 119,011 shares of the biotechnology company's stock after purchasing an additional 8,975 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Exelixis were worth $5,492,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of EXEL. Forum Financial Management LP purchased a new position in Exelixis during the 4th quarter valued at $241,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Exelixis during the 4th quarter valued at $11,998,000. NorthCrest Asset Manangement LLC boosted its holdings in Exelixis by 14.9% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 13,536 shares of the biotechnology company's stock valued at $451,000 after acquiring an additional 1,758 shares during the period. GAMMA Investing LLC boosted its holdings in Exelixis by 4,779.4% during the 1st quarter. GAMMA Investing LLC now owns 201,472 shares of the biotechnology company's stock valued at $7,438,000 after acquiring an additional 197,343 shares during the period. Finally, Merit Financial Group LLC boosted its holdings in Exelixis by 154.8% during the 1st quarter. Merit Financial Group LLC now owns 33,453 shares of the biotechnology company's stock valued at $1,235,000 after acquiring an additional 20,325 shares during the period. Hedge funds and other institutional investors own 85.27% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on EXEL. Jefferies Financial Group set a $50.00 price objective on Exelixis and gave the company a "buy" rating in a report on Tuesday, June 24th. Stifel Nicolaus boosted their price objective on Exelixis from $38.00 to $41.00 and gave the company a "hold" rating in a report on Tuesday, July 29th. JMP Securities restated a "market outperform" rating and set a $50.00 price objective on shares of Exelixis in a report on Tuesday, July 29th. Guggenheim reiterated a "buy" rating and issued a $45.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Finally, Zacks Research cut Exelixis from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 26th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.42.

Exelixis Price Performance

Shares of NASDAQ EXEL opened at $38.91 on Thursday. The stock has a market capitalization of $10.47 billion, a P/E ratio of 18.71, a price-to-earnings-growth ratio of 0.82 and a beta of 0.32. Exelixis, Inc. has a 1-year low of $25.17 and a 1-year high of $49.62. The business has a fifty day moving average price of $39.20 and a 200 day moving average price of $39.70.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. The firm had revenue of $568.26 million during the quarter, compared to analysts' expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm's quarterly revenue was down 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.